Efficacy and safety of exenatide as add‐on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double‐blind trial

Although we failed to reach our planned sample size, the addition of exenatide treatment 10 μg BID SC in T2D patients with uncontrolled HbA1c despite an intensified insulin regimen, resulted in a significant reduction of HbA1c and body weight with a good overall safety profile and acceptance.